Literature DB >> 10620438

VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.

B A Fine1, P T Valente, G I Feinstein, T Dey.   

Abstract

OBJECTIVE: Tumor angiogenesis is a highly regulated process under the influence of the host microenvironment and mediators. Studies of breast cancer and, more recently, ovarian and cervical cancer, demonstrate that neovascularization correlates with the likelihood of metastasis and recurrence. Vascular endothelial growth factor (VEGF), an important regulator of tumor angiogenesis in the endometrium, flt-1, and KDR/flk-1 are good markers of vascular proliferation. Being that angiogenesis is a precursor to the development of progressive disease, we hypothesize that quantifying VEGF, flt-1, and KDR/flk-1 expression in uterine malignancies is a superior predictor of metastatic potential and survival than is FIGO grade of tumor, depth of invasion, and histology.
METHODS: The histologic slides of 47 patients with uterine malignancies (35 adenocarcinomas, 6 papillary serous, and 6 carcinosarcomas) were reviewed. The paraffin blocks from the primary tumor were obtained. Immunohistochemistry staining was performed for VEGF, flt-1, and KDR/flk-1. Microvessel density, used to analyze VEGF and receptor concentrations, was determined by two independent investigators, who were blinded to the patients clinical status. The impact of VEGF, flt-1, and KDR/flk-1 as well as stage, grade, depth of invasion, and nodal status on the incidence of metastases, recurrence, and survival was determined using logistic regression analysis and product limit life system survival analysis, respectively.
RESULTS: Results indicated that when evaluating all three histologic types, only stage and grade of tumor were found to impact upon the incidence of recurrence and survival. When patients with carcinosarcoma and papillary serous adenocarcinoma were excluded from the analysis, once again only stage and grade of tumor were significant prognostic indicators of recurrence and survival. Only grade of tumor and depth of uterine invasion were significant predictors of a tumor's metastatic potential. VEGF, flt-1, and KDR/flk-1 proved to be of little significance in predicting metastases, recurrence, and survival. Patients with advanced disease in all three histologic subtypes often had low VEGF and receptor positivity.
CONCLUSIONS: In this study, VEGF, flt-1, and KDR/flk-1 receptor concentrations did not correlate with the incidence of metastases, recurrence, and survival. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620438     DOI: 10.1006/gyno.1999.5658

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.

Authors:  Laura Cerezo; Higinia Cárdenes; Helen Michael
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

2.  Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Wafaey Gomaa; Abdelbaset Buhmeida; Yousif Qari; Mohammad Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Tumour Biol       Date:  2014-06-09

3.  The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Authors:  Khalid A Mohamedali; Daniel Kedar; Paul Sweeney; Ashish Kamat; Darren W Davis; Beryl Y Eve; Samuel Huang; Philip E Thorpe; Colin P Dinney; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

4.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

Review 5.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

6.  Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Authors:  Sami K Saarelainen; Synnöve Staff; Nina Peltonen; Terho Lehtimäki; Jorma Isola; Paula M Kujala; Maarit H Vuento; Johanna U Mäenpää
Journal:  Tumour Biol       Date:  2014-01-14

7.  A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Heather A Lankes; Amanda Nickles Fader; Neil J Finkler; James S Hoffman; Peter G Rose; Gregory P Sutton; Charles W Drescher; D Scott McMeekin; Wei Hu; Michael Deavers; Andrew K Godwin; R Katherine Alpaugh; Anil K Sood
Journal:  Gynecol Oncol       Date:  2012-08-23       Impact factor: 5.482

Review 8.  The significance of markers in the diagnosis of endometrial cancer.

Authors:  Monika M Żyła; Jacek R Wilczyński; Marta Kostrzewa; Kinga Księżakowska-Łakoma; Marek Nowak; Grzegorz Stachowiak; Krzysztof Szyłło; Tomasz Stetkiewicz
Journal:  Prz Menopauzalny       Date:  2016-11-15

9.  Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.

Authors:  Chel Hun Choi; Sang Yong Song; Jung-Joo Choi; Young Ae Park; Heeseok Kang; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Je-Ho Lee; Duk-Soo Bae
Journal:  BMC Cancer       Date:  2008-10-11       Impact factor: 4.430

10.  Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer.

Authors:  C M Holland; K Day; A Evans; S K Smith
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.